Key result
The GLOBAL LEADERS trial is designed to evaluate whether 24-month ticagrelor monotherapy after 1 month of ASA improves outcomes compared to conventional DAPT following BES implantation.
Why the study?
Does a 24-month antithrombotic regimen with ticagrelor and one month of ASA improve outcomes compared to conventional DAPT in patients undergoing PCI with biolimus-eluting stents?
RCT (n=16,000)
1:1
Yes
Does a 24-month antithrombotic regimen with ticagrelor and one month of ASA improve outcomes compared to conventional DAPT in patients undergoing PCI with biolimus-eluting stents?
The GLOBAL LEADERS trial is designed to evaluate whether long-term ticagrelor monotherapy after 1 month of DAPT improves outcomes compared to standard DAPT in patients undergoing PCI.
Answers are grounded in this paper and cite their sources.
Tests ticagrelor monotherapy after 1-month ASA versus standard DAPT post-BES; leaves open optimal regimen until results emerge.
AIMS: The GLOBAL LEADERS trial is a superiority study in patients undergoing percutaneous coronary intervention, with a uniform use of Biolimus A9-eluting stents (BES) and bivalirudin. GLOBAL LEADERS was designed to assess whether a 24-month antithrombotic regimen with ticagrelor and one month of acetylsalicylic acid (ASA), compared to conventional dual antiplatelet therapy (DAPT), improves outcomes. METHODS AND RESULTS: Patients (n >16,000) are randomised (1:1 ratio) to ticagrelor 90 mg twice daily for 24 months plus ASA ≤100 mg for one month versus DAPT with either ticagrelor (acute coronary syndrome) or clopidogrel (stable coronary artery disease) for 12 months plus ASA ≤100 mg for 24 months. The primary outcome is a composite of all-cause mortality or non-fatal, new Q-wave myocardial infarction at 24 months. The key safety endpoint is investigator-reported class 3 or 5 bleeding according to the Bleeding Academic Research Consortium (BARC) definitions. Sensitivity analysis will be carried out to explore potential differences in outcome across geographic regions and according to specific angiographic and clinical risk estimates. CONCLUSIONS: The GLOBAL LEADERS trial aims to assess the role of ticagrelor as a single antiplatelet agent after a short course of DAPT for the long-term prevention of cardiac adverse events, across a wide spectrum of patients, following BES implantation.
No takes yet. Share an insight, caveat, or question.
Vranckx et al. (2016) conducted an RCT in Percutaneous coronary intervention (n=16,000). Ticagrelor monotherapy vs. DAPT with either ticagrelor or clopidogrel for 12 months plus ASA ≤100 mg for 24 months was evaluated on Composite of all-cause mortality or non-fatal, new Q-wave myocardial infarction at 24 months. The GLOBAL LEADERS trial is designed to evaluate whether 24-month ticagrelor monotherapy after 1 month of ASA improves outcomes compared to conventional DAPT following BES implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: